KPV vs TB-500
A side-by-side research comparison of KPV and TB-500 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | KPV | TB-500 |
|---|---|---|
| Full name | Lysine-Proline-Valine Tripeptide | Thymosin Beta-4 (Synthetic) |
| Category | Healing & Recovery | Healing & Recovery |
| Status | Research compound | Research compound |
| Mechanism | Inhibits NF-kB signaling pathway, reduces pro-inflammatory cytokine production (TNF-α, IL-6), and modulates immune cell activation. | Upregulates actin production to promote cell migration and proliferation, enhances angiogenesis, and reduces pro-inflammatory cytokines. |
| Molecular weight | 342.43 Da | 4921 Da |
| Half-life | ~2-3 hours | ~6 hours |
| Bioavailability | ~60-70% oral; higher subcutaneous | ~95% via subcutaneous injection |
| Typical dose | 200-500 mcg per dose | 2-5 mg per dose |
| Frequency | 1-2x daily | Loading: 2x/week · Maintenance: 1x/week |
| Route | Oral, topical, or subcutaneous | Subcutaneous injection |
KPV reported benefits
- Potent anti-inflammatory
- Gut inflammation reduction
- Skin condition improvement
- Immune modulation
TB-500 reported benefits
- Enhanced wound healing
- Reduced inflammation
- Improved flexibility
- Cardiac tissue repair
- Hair regrowth support
Related comparisons
Research and educational reference only. Not medical advice.